NASDAQ:VKTXViking Therapeutics Stock Price, Forecast & News

Viking Therapeutics' stock was trading at $5.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VKTX shares have increased by 31.8% and is now trading at $6.68. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viking Therapeutics.

Viking Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Viking Therapeutics.

Viking Therapeutics Inc (NASDAQ:VKTX) posted its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. View Viking Therapeutics' earnings history.

13 Wall Street analysts have issued 1-year price objectives for Viking Therapeutics' shares. Their forecasts range from $9.00 to $25.00. On average, they expect Viking Therapeutics' stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price. View analysts' price targets for Viking Therapeutics.

Press coverage about VKTX stock has trended negative on Monday, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viking Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Viking Therapeutics.

Viking Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 11,210,000 shares, a decline of 8.5% from the May 31st total of 12,250,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is presently 6.5 days. Currently, 15.9% of the company's stock are short sold. View Viking Therapeutics' Current Options Chain.

Some companies that are related to Viking Therapeutics include Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Xencor (XNCR), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), Myovant Sciences (MYOV), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Akebia Therapeutics (AKBA), INDIVIOR PLC/S (INVVY), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB) and Zymeworks (ZYME). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Energy Transfer LP Unit (ET), Micron Technology (MU), Crispr Therapeutics (CRSP) and SCYNEXIS (SCYX).

(VKTX) raised $20 million in an initial public offering on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VKTX stock can currently be purchased for approximately $6.68.

Viking Therapeutics has a market capitalization of $484.97 million. The biotechnology company earns $-25,780,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Viking Therapeutics employs 17 workers across the globe.

The official website for Viking Therapeutics is www.vikingtherapeutics.com.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]